Dépistage du cancer du poumon : que dire à nos patient·e·s en attendant un programme organisé ? [Lung cancer screening: what can we tell our patients while we await a screening program ?]
Details
State: Public
Version: Final published version
License: CC BY-NC-ND 4.0
Serval ID
serval:BIB_FC6D286D8FE3
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Dépistage du cancer du poumon : que dire à nos patient·e·s en attendant un programme organisé ? [Lung cancer screening: what can we tell our patients while we await a screening program ?]
Journal
Revue medicale suisse
ISSN
1660-9379 (Print)
ISSN-L
1660-9379
Publication state
Published
Issued date
04/11/2020
Peer-reviewed
Oui
Volume
16
Number
713
Pages
2086-2091
Language
french
Notes
Publication types: Journal Article
Publication Status: ppublish
Publication Status: ppublish
Abstract
The NLST study in the United States showed, in 2011, that low-dose lung CT scans can reduce lung cancer mortality but was limited in its routine recommendation by 96% of false positive screening results. The European NELSON trial, published in 2020, confirmed a 24% decrease in lung cancer mortality and, by using lung nodule volume and volume doubling time, decreased false positive results to 56% of positive tests. The implementation of screening programs is now expected in Europe, including Switzerland. In anticipation, we have developed a decision aid to present patients with the benefits (decreased lung cancer mortality), risks (false positives and indeterminate results), and uncertainties (incidental findings) of lung cancer screening.
Keywords
Early Detection of Cancer, Europe, Humans, Lung Neoplasms/diagnostic imaging, Lung Neoplasms/epidemiology, Mass Screening, Switzerland/epidemiology, United States
Pubmed
Create date
09/11/2020 9:22
Last modification date
29/06/2023 7:40